These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 16354393)
21. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort. Shireman TI; Rigler SK Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321 [TBL] [Abstract][Full Text] [Related]
23. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558 [TBL] [Abstract][Full Text] [Related]
24. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. Schüssel K; Schulz M Pharmazie; 2006 Oct; 61(10):878-86. PubMed ID: 17069430 [TBL] [Abstract][Full Text] [Related]
25. Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. Fiorucci S Gastroenterol Clin North Am; 2009 Jun; 38(2):315-32. PubMed ID: 19446261 [TBL] [Abstract][Full Text] [Related]
26. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. Salinas G; Rangasetty UC; Uretsky BF; Birnbaum Y J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):98-111. PubMed ID: 17562780 [TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise? Pruthi RS; Kouba E; Carson CC; Wallen EM Urology; 2006 Nov; 68(5):917-23. PubMed ID: 17113880 [No Abstract] [Full Text] [Related]
28. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do? Lazzaroni M; Battocchia A; Bianchi Porro G Dig Liver Dis; 2007 Jun; 39(6):589-96. PubMed ID: 17459794 [TBL] [Abstract][Full Text] [Related]
29. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859 [TBL] [Abstract][Full Text] [Related]
31. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591 [TBL] [Abstract][Full Text] [Related]
32. Signalling networks regulating cyclooxygenase-2. Tsatsanis C; Androulidaki A; Venihaki M; Margioris AN Int J Biochem Cell Biol; 2006; 38(10):1654-61. PubMed ID: 16713323 [TBL] [Abstract][Full Text] [Related]
33. Putting the vasoactive effects of COX-2-derived prostanoids into clinical perspective. Krötz F Cardiovasc Res; 2009 Feb; 81(2):240-1. PubMed ID: 19073628 [No Abstract] [Full Text] [Related]
34. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against. Weber AA; Hohlfeld T; Harder S Thromb Haemost; 2006 Oct; 96(4):413-6. PubMed ID: 17003916 [TBL] [Abstract][Full Text] [Related]
35. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797 [TBL] [Abstract][Full Text] [Related]
36. Update on the role of nonsteroidal anti-inflammatory drugs and coxibs in the management of acute pain. Reuben SS Curr Opin Anaesthesiol; 2007 Oct; 20(5):440-50. PubMed ID: 17873597 [TBL] [Abstract][Full Text] [Related]
37. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544 [TBL] [Abstract][Full Text] [Related]